One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility

Mohammadpour, Raziye; Cheney, D. L.; Grunberger, Jason William; Yazdimamaghani, Mostafa; Jedrzkiewicz, Jolanta; Isaacson, Kyle J.; Dobrovolskaia, Marina A.; Ghandehari, Hamidreza

doi:10.1016/j.jconrel.2020.05.027

Cited by 71 publications

(38 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, long-term toxicity studies about the chronic administration of MSN are needed. Recently, Mohammadpour et al have evaluated the effect of the intravenous administration of silica nanoparticles with different sizes and porosities for one year in animal models showing scarce toxicity [ 85 ]. The development of industrial synthetic routes which yield large amounts of high quality MSN with reproducibility between batches is also a challenge.…”

Section: Discussionmentioning

confidence: 99%

Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines

Baeza

Vallet‐Regí

2020

Pharmaceutics

View full text Add to dashboard Cite

Nanoparticles have become a powerful tool in oncology not only as carrier of the highly toxic chemotherapeutic drugs but also as imaging contrast agents that provide valuable information about the state of the disease and its progression. The enhanced permeation and retention effect for loaded nanocarriers in tumors allow substantial improvement of selectivity and safety of anticancer nanomedicines. Additionally, the possibility to design stimuli-responsive nanocarriers able to release their payload in response to specific stimuli provide an excellent control on the administered dosage. The aim of this review is not to present a comprehensive revision of the different theranostic mesoporous silica nanoparticles (MSN) which have been published in the recent years but just to describe a few selected examples to offer a panoramic view to the reader about the suitability and effectiveness of these nanocarriers in the oncology field.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines

Baeza

Vallet‐Regí

2020

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The major toxicity pathway associated with silica is due to its surface chemistry (silanol groups) which can interact with the membrane components leading to the cells lysis and cellular components leaking (91,92). Mesoporous silica exhibited lower hemolytic effect compared to non-porous silica (25). This could be attributed to the lower density of silanol groups on the surface of mesoporous structures (93).…”

Section: Biocompatibility and Biodistributionmentioning

confidence: 99%

“…Specifically, inorganic platforms as mesoporous silica nanoparticles (MSNs) comprise a potential nanosystem for healthcare applications due to interesting characteristics such as easy functionalization, large surface area, high chemical and physical stabilities and hydroxyl groups available in their surface/ pores. In addition, MSNs tunable morphology, size, surface charges and pores make them carriers with good biocompatibility and biodegradability, low toxicity, good biodistribution and elimination (12,(21)(22)(23)(24)(25)(26)(27). Drugs loaded into MSNs pores leading to pharmacological properties maintenance besides protection against degradation and immediate drug release (23,24,28,29).…”

Section: Introductionmentioning

confidence: 99%

Highlights in Mesoporous Silica Nanoparticles as a Multifunctional Controlled Drug Delivery Nanoplatform for Infectious Diseases Treatment

et al. 2020

View full text Add to dashboard Cite

Infectious diseases are a major global concern being responsible for high morbidity and mortality mainly due to the development and enhancement of multidrug-resistant microorganisms exposing the fragility of medicines and vaccines commonly used to these treatments. Taking into account the scarcity of effective formulation to treat infectious diseases, nanotechnology offers a vast possibility of groundbreaking platforms to design new treatment through smart nanostructures for drug delivery purposes. Among the available nanosystems, mesoporous silica nanoparticles (MSNs) stand out due their multifunctionality, biocompatibility and tunable properties make them emerging and actual nanocarriers for specific and controlled drug release. Considering the high demand for diseases prevention and treatment, this review exploits the MSNs fabrication and their behavior in biological media besides highlighting the most of strategies to explore the wide MSNs functionality as engineered, smart and effective controlled drug release nanovehicles for infectious diseases treatment.

show abstract

“…As long as the silica doses are not too large, this would prevent chronic accumulation in the organism. A recent study that evaluated the one-year toxicological behavior of intravenously-injected single-dose silica nanoparticles in mice has shown that, while large (500 nm) non-porous silica particles produced some lung, heart and kidney damage attributed to resolved thrombosis, no significant toxicity was produced by MSNs and smaller non-porous silica particles [ 35 ].…”

Section: Mesoporous Silica Nanoparticles For Drug Deliverymentioning

confidence: 99%

Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review

Paris

Vallet‐Regí

2020

Pharmaceutics

View full text Add to dashboard Cite

Mesoporous silica nanoparticles have attracted much attention in recent years as drug and gene delivery systems for biomedical applications. Among their most beneficial features for biomedicine, we can highlight their biocompatibility and their outstanding textural properties, which provide a great loading capacity for many types of cargos. In the context of cancer nanomedicine, combination therapy and gene transfection/silencing have recently been highlighted as two of its most promising fields. In this review, we aim to provide an overview of the different small molecule drug-nucleic acid co-delivery combinations that have been developed using mesoporous silica nanoparticles as carriers. By carefully selecting the chemotherapeutic drug and nucleic acid cargos to be co-delivered by mesoporous silica nanoparticles, different therapeutic goals can be achieved by overcoming resistance mechanisms, combining different cytotoxic mechanisms, or providing an additional antiangiogenic effect. The examples here presented highlight the great promise of this type of strategies for the development of future therapeutics.

show abstract

One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility

Cited by 71 publications

References 66 publications

Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines

Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines

Highlights in Mesoporous Silica Nanoparticles as a Multifunctional Controlled Drug Delivery Nanoplatform for Infectious Diseases Treatment

Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review

Contact Info

Product

Resources

About